You have reached your monthly allowance of 1 free premium articles from The Pharmaceutical Journal and Clinical Pharmacist. Sign in or register for free to access 2 more articles. Subscribe for full access to The Pharmaceutical Journal and Clinical Pharmacist and CPD modules.
Use the code0516EMSB2DP for 20% discount on our annual digital subscriptions.
Tuberculosis (TB) remains a significant global health and socioeconomic challenge. The duration of current anti-TB therapies, the adverse effects of certain anti-TB drugs and the growing problem of drug-resistant TB on an international scale mean that it is imperative for new, effective and safe treatment regimens to be developed. Fluoroquinolones are a class of drugs that have been used in the treatment of TB for several decades. This article provides an overview of the current treatment ...
Are you already a registered user or a member of the Royal Pharmaceutical Society?Sign in here
Subscribe for as little as £5, to gain full, unlimited access to the ultimate source of information and news on pharmacy and pharmaceutical sciences.Subscribe today
Alternatively, register for free to the site for access to an extra 2 premium articles for free.Register now.
Please contact The Pharmaceutical Journal directly, so we can provide you with detailed information about our institutional and corporate offerings.
Tel: +44 (0)20 7572 2221
As a pharmacist or pharmaceutical scientist, join the Royal Pharmaceutical Society and gain full access to pharmaceutical-journal.com
Membership is free for pharmacy students.
If you are not registered as a pharmacist in Great Britain or practise overseas, you may still be able to join the RPS as an associate member.Become a member